Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC filings relevant to Helius Medical Tech WT 26 (HSDTW), a warrant security associated with Helius Medical Technologies, Inc. The company files under the name Helius Medical Technologies, Inc., and its Class A common stock is listed on The Nasdaq Stock Market LLC under the symbol HSDT, as stated in multiple Form 8-K reports.
In recent Form 8-K filings, the company reports material definitive agreements involving private offerings of common stock, pre-funded warrants, stapled warrants, and warrants issued to strategic advisors. These filings describe cash and cryptocurrency-based offerings with accredited investors, where consideration may be paid in U.S. dollars, USDC, USDT, or Solana (SOL) tokens. The documents also outline lock-up provisions, stockholder approval requirements for the exercise of certain warrants, and registration rights for the resale of underlying shares.
For investors analyzing HSDTW and related securities, key filings include Form 8-K items on unregistered sales of equity securities, securities purchase or subscription agreements, strategic advisor agreements, and amendments to the company’s authorized share capital. The filings further state that net proceeds from the offerings are intended to fund the acquisition of SOL through open market purchases, support Solana treasury operations, and provide working capital and general corporate funds, subject to specified limitations.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that explain the core terms of each document, highlight important conditions affecting warrants and common stock, and help readers understand complex capital structure changes. Real-time updates from EDGAR, along with structured access to Form 8-K items and related exhibits, allow users to review how Helius Medical Technologies, Inc. discloses its financing activities and warrant arrangements that underpin the HSDTW security.
Solana Company is selling 3,076,922 shares of Class A common stock in a registered direct offering at $2.60 per share for a total offering price of $7,999,997.20, with delivery expected on or about April 28, 2026.
The company expects net proceeds of approximately $7.9 million to be used for accumulating SOL, working capital, general corporate purposes, business expansion and strategic initiatives. The offering is made under a Form S-3 shelf registration and assumes no exercise of outstanding warrants.
Solana Company is selling 3,076,922 shares of Class A common stock in a registered direct offering at $2.60 per share for a total offering price of $7,999,997.20, with delivery expected on or about April 28, 2026.
The company expects net proceeds of approximately $7.9 million to be used for accumulating SOL, working capital, general corporate purposes, business expansion and strategic initiatives. The offering is made under a Form S-3 shelf registration and assumes no exercise of outstanding warrants.
Solana Company entered into securities purchase agreements for a registered direct offering of 3,076,922 shares of Class A common stock at $2.60 per share, generating expected gross proceeds of about $8 million and net proceeds of about $7.9 million.
The company plans to use the cash to accumulate SOL tokens, fund working capital, support general corporate purposes, business expansion and other strategic initiatives. In connection with the deal, Solana Company granted purchasers put options allowing them, upon specified future events, to require the company to repurchase their shares at the original purchase price plus an internal rate of return of 7.0% per annum.
Solana Company entered into securities purchase agreements for a registered direct offering of 3,076,922 shares of Class A common stock at $2.60 per share, generating expected gross proceeds of about $8 million and net proceeds of about $7.9 million.
The company plans to use the cash to accumulate SOL tokens, fund working capital, support general corporate purposes, business expansion and other strategic initiatives. In connection with the deal, Solana Company granted purchasers put options allowing them, upon specified future events, to require the company to repurchase their shares at the original purchase price plus an internal rate of return of 7.0% per annum.
Solana Company reported upcoming changes to its Board of Directors. Sherrie Perkins and Paul Buckman told the company they will not stand for re-election when their current terms end at the 2026 Annual Meeting of Stockholders on May 21, 2026. The company states their decisions are not due to any disagreement over operations, policies, practices, strategy, management, or the Board.
On April 23, 2026, the Board increased its size from seven to nine members and appointed Michel Lee and Sergio Mello to fill the new seats, effective immediately. Both will receive cash and equity compensation under the existing non-employee director compensation policy and will be covered by the company’s standard indemnification agreement for directors and officers.
Solana Company reported upcoming changes to its Board of Directors. Sherrie Perkins and Paul Buckman told the company they will not stand for re-election when their current terms end at the 2026 Annual Meeting of Stockholders on May 21, 2026. The company states their decisions are not due to any disagreement over operations, policies, practices, strategy, management, or the Board.
On April 23, 2026, the Board increased its size from seven to nine members and appointed Michel Lee and Sergio Mello to fill the new seats, effective immediately. Both will receive cash and equity compensation under the existing non-employee director compensation policy and will be covered by the company’s standard indemnification agreement for directors and officers.
Solana Company announced that Antonella Favit‑Van Pelt, MD, PhD, has mutually agreed with the company to resign as Chief Medical Officer, effective April 8, 2026. The parties entered into a Separation Agreement effective the same date.
Under this agreement, Dr. Favit‑Van Pelt will receive a lump‑sum separation payment of $875,000, less applicable withholdings, to be paid within ten business days after the effective date. In return, she waives and releases employment‑related claims and must continue to honor confidentiality and invention assignment obligations from her employment agreement.
Solana Company announced that Antonella Favit‑Van Pelt, MD, PhD, has mutually agreed with the company to resign as Chief Medical Officer, effective April 8, 2026. The parties entered into a Separation Agreement effective the same date.
Under this agreement, Dr. Favit‑Van Pelt will receive a lump‑sum separation payment of $875,000, less applicable withholdings, to be paid within ten business days after the effective date. In return, she waives and releases employment‑related claims and must continue to honor confidentiality and invention assignment obligations from her employment agreement.
Solana Company is soliciting proxies for its 2026 Annual Meeting of Stockholders, to be held virtually on May 21, 2026 at 9:00 a.m. ET. Holders of its Class A common stock as of April 1, 2026, when 54,889,569 shares were outstanding, may vote.
Stockholders will elect seven directors and vote on ratifying CBIZ as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting FOR all director nominees and FOR Proposal 2.
The filing details board independence, leadership structure and committee assignments, and outlines executive pay. In 2025, CEO Dane Andreeff received total compensation of $2.1 million, CFO Jeffrey Mathiesen received $1.5 million, and Executive Chairman Joseph Chee received $6.9 million, including 1,109,118 RSUs tied to a 2025 private placement and digital asset treasury work. The proxy also describes change-in-control severance protections, a clawback policy for erroneously awarded compensation, and the company’s insider trading and board governance policies.
Solana Company is soliciting proxies for its 2026 Annual Meeting of Stockholders, to be held virtually on May 21, 2026 at 9:00 a.m. ET. Holders of its Class A common stock as of April 1, 2026, when 54,889,569 shares were outstanding, may vote.
Stockholders will elect seven directors and vote on ratifying CBIZ as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting FOR all director nominees and FOR Proposal 2.
The filing details board independence, leadership structure and committee assignments, and outlines executive pay. In 2025, CEO Dane Andreeff received total compensation of $2.1 million, CFO Jeffrey Mathiesen received $1.5 million, and Executive Chairman Joseph Chee received $6.9 million, including 1,109,118 RSUs tied to a 2025 private placement and digital asset treasury work. The proxy also describes change-in-control severance protections, a clawback policy for erroneously awarded compensation, and the company’s insider trading and board governance policies.
Solana Company appointed Agustina “Madelene” Gani Tjandrasuwita as Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026. She brings more than 25 years of global finance experience across crypto, fintech, and public companies, including senior roles at Hedera Hashgraph, Aptos Labs, Gemini, and JUUL Labs.
Under an Offer Letter dated March 13, 2026, she will receive a $350,000 annual base salary, be eligible for an annual target bonus equal to 40% of base salary, and additional equity incentives with a combined target value of $300,000 to $500,000. After three months, subject to board approval, she is also eligible for a one-time stock option grant with a grant date fair value of $75,000, vesting over four years.
Solana Company appointed Agustina “Madelene” Gani Tjandrasuwita as Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026. She brings more than 25 years of global finance experience across crypto, fintech, and public companies, including senior roles at Hedera Hashgraph, Aptos Labs, Gemini, and JUUL Labs.
Under an Offer Letter dated March 13, 2026, she will receive a $350,000 annual base salary, be eligible for an annual target bonus equal to 40% of base salary, and additional equity incentives with a combined target value of $300,000 to $500,000. After three months, subject to board approval, she is also eligible for a one-time stock option grant with a grant date fair value of $75,000, vesting over four years.
Solana Co officer Tjandrasuwita Agustina Gani, listed as COO & Deputy CFO, has filed an insider ownership report for the company. The filing shows no insider stock transactions or derivative positions, indicating only the reporting of status as an officer without buy or sell activity.
Solana Co officer Tjandrasuwita Agustina Gani, listed as COO & Deputy CFO, has filed an insider ownership report for the company. The filing shows no insider stock transactions or derivative positions, indicating only the reporting of status as an officer without buy or sell activity.
Solana Co director Sherrie L. Perkins reported equity compensation awards. She received a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. She was also granted 2,180 shares of Class A Common Stock as restricted stock units under the 2022 Equity Incentive Plan. According to the awards’ terms, 75% of both the RSUs and options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, subject to her continued service. Following the stock grant, she directly holds 92,220 shares of Class A Common Stock.
Solana Co director Sherrie L. Perkins reported equity compensation awards. She received a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. She was also granted 2,180 shares of Class A Common Stock as restricted stock units under the 2022 Equity Incentive Plan. According to the awards’ terms, 75% of both the RSUs and options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, subject to her continued service. Following the stock grant, she directly holds 92,220 shares of Class A Common Stock.
Solana Co director Paul Buckman received new equity awards as part of his compensation. He was granted a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036.
He also received 2,180 shares of Class A Common Stock, increasing his direct holdings to 92,004 shares. Both the option and restricted stock units vest 75% on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, contingent on his continued service.
Solana Co director Paul Buckman received new equity awards as part of his compensation. He was granted a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036.
He also received 2,180 shares of Class A Common Stock, increasing his direct holdings to 92,004 shares. Both the option and restricted stock units vest 75% on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, contingent on his continued service.
Solana Co director Walter Blane received new equity awards in the form of stock options and restricted stock units. He was granted stock options covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. He also received 2,180 shares of Class A Common Stock from a grant classified as a restricted stock unit award. According to the award terms, 75% of both the RSUs and the options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, if he continues in service.
Solana Co director Walter Blane received new equity awards in the form of stock options and restricted stock units. He was granted stock options covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. He also received 2,180 shares of Class A Common Stock from a grant classified as a restricted stock unit award. According to the award terms, 75% of both the RSUs and the options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, if he continues in service.